What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

CF Industries (NYSE:CF) -6.8% in Friday's trading as J.P. Morgan downgrades shares to Underweight from Neutral with a $75 ...

J.P. Morgan downgraded PVH Corp (NYSE:PVH) to "Neutral" on a slower-than-expected recovery in topline growth amid global macroeconomic challenges and foreign exchange pressures.

J.P. Morgan analyst Ranjan Sharma maintained a Buy rating on Grab (GRAB – Research Report) on January 21 and set a price target of $5.60. The ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

Jamie Dimon, chairman and CEO, noted in the release that in the asset and wealth management division client net inflows ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers ...

J.P. Morgan analyst Mark Strouse maintained a Hold rating on Bloom Energy (BE – Research Report) yesterday and set a price target of $16.00.

The Westin St. Francis Hotel in Union Square will once again be host for one of the biggest conventions in the city--the J.P.

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...

Investing.com -- J.P. Morgan analysts have upgraded their rating for Aviva plc (LON: AV) to "overweight" from "neutral," ...